Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Hold” by Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given an average recommendation of “Hold” by the six research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $27.8333.

Several research analysts have recently weighed in on the stock. BTIG Research lifted their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday. They set a “market perform” rating on the stock. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, The Goldman Sachs Group lowered their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares in the company, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in KMTS. Russell Investments Group Ltd. increased its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Kestra Medical Technologies by 7.3% in the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after purchasing an additional 874 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the fourth quarter worth about $31,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its position in shares of Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after buying an additional 1,392 shares in the last quarter.

Kestra Medical Technologies Trading Up 3.3%

Kestra Medical Technologies stock opened at $21.57 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The stock has a market capitalization of $1.26 billion, a PE ratio of -8.91 and a beta of 0.47. The business’s fifty day moving average is $22.30 and its 200 day moving average is $22.57. Kestra Medical Technologies has a one year low of $14.10 and a one year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million for the quarter. On average, sell-side analysts predict that Kestra Medical Technologies will post -2.29 EPS for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.